TXMD - TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business
- TherapeuticsMD had a rough 2021, and the share price shows it. The company battled the COVID-19 headwinds and has struggled to expand ANNOVERA’s manufacturing.
- TherapeuticsMD has an imposing product portfolio. Sadly, the company’s products have struggled to gain traction on the market, and the earnings show it.
- TherapeuticsMD is selling their vitaCare prescription health business to GoodRx for $150M in cash, with an extra $7M in contingent. The company can pay off some of their debt.
- I believe there is a chance we finally see a turnaround for TXMD. I discuss my plan for managing my position.
- I have the buy target at $0.35 with Sell 1 at $0.67 and Sell 2 at $1.49. I do have a Sell 3 at $2.14, however, I am probably going to have to adjust that in the coming weeks as the chart’s technicals change.
For further details see:
TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business